Alumis Inc. Reports Q2 2025 Earnings and Strategic Advances

Alumis Inc. ( (ALMS) ) has released its Q2 earnings. Here is a breakdown of the information Alumis Inc. presented to its investors.

Alumis Inc., a clinical-stage biopharmaceutical company, focuses on developing next-generation targeted therapies for immune-mediated diseases, leveraging its proprietary data analytics platform to advance its pipeline of treatments.

In its second quarter of 2025, Alumis Inc. reported significant progress in its clinical trials and corporate developments. The company completed patient enrollment for its Phase 3 ONWARD clinical trials for plaque psoriasis and Phase 2b LUMUS trial for systemic lupus erythematosus. Additionally, Alumis finalized a merger with ACELYRIN, Inc., enhancing its financial position to support its late-stage immunology pipeline.

Alumis reported cash, cash equivalents, and marketable securities totaling $486.3 million as of June 30, 2025, expected to fund operations into 2027. The company recorded a net income of $59.3 million for the quarter, a significant turnaround from a net loss in the previous year, largely due to a non-operating gain from the merger. Research and development expenses increased, driven by clinical trial costs and merger-related expenses.

Strategically, Alumis is advancing its TYK2 inhibitor programs, with envudeucitinib progressing in trials for plaque psoriasis and lupus, and A-005 moving towards a Phase 2 trial for multiple sclerosis. The company also received Fast Track Designation for lonigutamab for thyroid eye disease, underscoring its commitment to addressing unmet medical needs.

Looking ahead, Alumis remains focused on advancing its pipeline through key clinical milestones, with expectations of reduced research and development expenses in the coming quarters. The company is poised to participate in several investor conferences, signaling its active engagement with the financial community as it progresses towards its strategic goals.